In lab studies, APVO451 and APVO452 helped immune cells kill cancer cells despite conditions that suppress immune activity - offering potential for difficult-to-treat solid tumorsPreclinical work also showed that
Refined priming-dose regimen addresses important treatment-tolerability objective identified through FDA discussions, further strengthening mipletamig's readiness for Phase 2 developmentSubstantial reduction in
Ten patients initially deemed unfit for intensive chemotherapy proceeded to stem cell transplantTransplant rate compares favorably with historical standard-of-care experience, adding to growing clinical evidence
Next generation multispecific technology designed to coordinate innate and adaptive immune activity within the tumor microenvironment
SEATTLE, WA / ACCESS Newswire / October 14, 2026 / Aptevo Therapeutics Inc.
Company Making Critical Progress in Scalable Manufacturing and Preparing the Lead Trispecific Candidate for Future Human TestingTrispecifics Combine Three Complementary Cancer-Fighting Functions in One Molecule,
Remission results nearly double published ven/aza outcomes in patients with historically limited treatment success SEATTLE, WA / ACCESS Newswire / September 3, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a
SEATTLE, WA / ACCESS Newswire / August 13, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology
SEATTLE, WA / ACCESS Newswire / August 12, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO) ("Aptevo" or the "Company"), a clinical-stage biotechnology company developing novel multispecific immuno-oncology
Filing supports potential development of radiopharmaceuticals, T-cell engagers and other immune-based approaches using a versatile platform approach SEATTLE, WA / ACCESS Newswire / July 27, 2026 / Aptevo Therapeutics
SEATTLE, WA / ACCESS Newswire / June 30, 2026 / Aptevo Therapeutics Inc. (NASDAQ:APVO), a clinical-stage biotechnology company developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and
Experienced oncology R&D leader appointed to support Aptevo's expanding oncology pipeline and new radiopharmaceutical development strategy SEATTLE, WA / ACCESS Newswire / May 28, 2026 / Aptevo Therapeutics Inc.
50/50 Strategic Collaboration Will Develop Up to Three Radiopharmaceutical ProgramsInnovation and Investment Continue to Accelerate Across Radiopharmaceutical Oncology SEATTLE, WA AND LANSING, MI / ACCESS Newswire / May
Mipletamig continues to perform, delivers 87% clinical benefit and 81% remission in frontline AML, with no CRS in frontline patientsExecutive leadership transition complete. Jeff Lamothe appointed CEO; Marvin White
Program Enters Final Stage of Dose OptimizationData Continue to Demonstrate Strong Clinical Activity and Favorable Safety Across an Expanding Frontline Dataset SEATTLE, WA / ACCESS Newswire / May 6, 2026 / Aptevo
